- Replimune takes third swing at cancer drug approval following ‘productive’ FDA talks<figure><div><img src="https://imgproxy.divecdn.com/KkNxfSBTkY2VjB8ICSuee0jTuqLQfv0D9hMURCyAiqU/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMjI3NzEwNDcyX1h1c…BioPharma Dive · 1mo ago↗ source
- AstraZeneca seeks path for failed antibody; Imfinzi, Tremfya get label expansions🔎 AstraZeneca narrows path for failed antibody: The company announced last summer that its monoclonal antibody anselamimab missed the primary endpoint in a pair of Phase 3 trials for patients with…Endpoints · 1mo ago↗ source
- Replimune will again submit its melanoma drug for approvalThird time’s the charm? Replimune announced Friday that it will submit its advanced melanoma drug RP1 for FDA review after two prior rejections. It said it has had new discussions with ...